Patel, Hitendra
Okamura, Ryosuke http://orcid.org/0000-0001-7352-8621
Fanta, Paul
Patel, Charmi
Lanman, Richard B.
Raymond, Victoria M.
Kato, Shumei
Kurzrock, Razelle
Funding for this research was provided by:
The Joan and Irwin Jacobs Fund
National Cancer Institute (P30 CA023100)
Article History
Received: 29 July 2019
Accepted: 8 November 2019
First Online: 4 December 2019
Ethics approval and consent to participate
: All investigations followed the guidelines of UC San Diego Moores Cancer Center Internal Review Board and were performed in accordance with the Declaration of Helsinki under the auspices of our approved study (NCT02478931) and any investigational therapy. Written informed consent was obtained from each patient.
: Not applicable
: RK has the following disclosure information: Leadership (CureMatch, Inc); Stock and Other Ownership Interests ( IDbyDNA, CureMatch, Inc., and Soluventis); Consulting or Advisory Role (Gaido, LOXO, X-Biotech, Actuate Therapeutics, Roche, NeoMed, and Soluventis); Speaker’s fee (Roche); Research Funding (Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, Grifols, Konica Minolta, and OmniSeq [All insts]). RBL has a leadership position at Guardant Health and RBL and VMR are employees and own stock at Guardant Health. The other authors have no competing interests to this work.